A practical reference on lyophilization: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
One study has found that these steroid-carrier complexes are bound by megalin, a membrane receptor, and are then taken into cells via endocytosis. One possible pathway is that once inside the cell these complexes are taken to the lysosome, where the carrier protein is degraded and the steroid hormone is released into the cytoplasm of the target cell. The hormone then follows a genomic pathway of action. This process is shown in Figure 2 to the right. The role of endocytosis in steroid hormone transport is not well understood and is under further investigation. In order for steroid hormones to cross the lipid bilayer of cells, they must overcome energetic barriers that would prevent their entering or exiting the membrane. Gibbs free energy is an important concept here. These hormones, which are all derived from cholesterol, have hydrophilic functional groups at either end and hydrophobic carbon backbones. When steroid hormones are entering membranes free energy barriers exist when the functional groups are entering the hydrophobic interior of membrane, but it is energetically favorable for the hydrophobic core of these hormones to enter lipid bilayers. These energy barriers and wells are reversed for hormones exiting membranes. Steroid hormones easily enter and exit the membrane at physiologic conditions. They have been shown experimentally to cross membranes near a rate of 20 μm/s, depending on the hormone. Though it is energetically more favorable for hormones to be in the membrane than in the ECF or ICF, they do in fact leave the membrane once they have entered it.
== Etymology == The word emulsion comes from the Latin emulgere 'to milk out', from ex 'out' + mulgere 'to milk', as milk is an emulsion of fat and water, along with other components, including colloidal casein micelles (a type of secreted biomolecular condensate).
== History == Colonies of B. cereus were originally isolated by Percy F. Frankland from a gelatine plate left exposed to the air in a cow shed in 1887. In the 2010s, examination of warning letters issued by the US Food and Drug Administration issued to pharmaceutical manufacturing facilities addressing facility microbial contamination revealed that the most common contaminant was B. cereus. Several new enzymes have been discovered in B. cereus, such as AlkC and AlkD, both of which are involved in DNA repair.
== Adverse effects == Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, fatigue, weakness, palpitations, and nausea. Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, anxiety, nasal congestion, and rash. A very rare side effect of prazosin is priapism. One phenomenon associated with prazosin is known as the "first-dose response", in which the side effects of the drug—specifically orthostatic hypotension, dizziness, and drowsiness—are especially pronounced in the first dose. Orthostatic hypotension and syncope are associated with the body's poor ability to control blood pressure without active α-adrenergic receptors. The nasal congestion is exacerbated by changing body positions, because α1-adrenergic receptors also control nasal vascular blood flow and alpha blockers inhibit this, in the same way that alpha-adrenergic agonists have the opposite effect of being a decongestant.
== Interactions == Remdesivir is at least partially metabolized by the cytochrome P450 enzymes CYP2C8, CYP2D6, and CYP3A4. Blood plasma concentrations of remdesivir are expected to decrease if it is administered together with cytochrome P450 inducers such as rifampicin, carbamazepine, phenobarbital, phenytoin, primidone, and St John's wort. Using chloroquine or hydroxychloroquine with remdesivir may reduce the antiviral activity of remdesivir. Coadministration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on in vitro data demonstrating an antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of remdesivir.
Sources: en.wikipedia.org
Herein, the electron donor NADPH is used as the reducing agent, ultimately converting the β-keto group of β-ketoacyl-ACP into the β-hydroxyl group of β-hydroxyacyl-ACP. The fifth step of fatty acid elongation is the dehydration of β-hydroxyacyl-ACP to enoyl-ACP, in a reaction catalyzed by 3-hydroxyacyl-ACP dehydratase. 3-hydroxyacyl-ACP dehydratase removes one molecule of H2O to form a double bond between the C2–C3 carbons of β-hydroxyacyl-ACP, thereby saturating the chain and producing enoyl-ACP. The sixth step of fatty acid elongation is the reduction of enoyl-ACP to butyryl-ACP, in a reaction catalyzed by enoyl-ACP reductase. Herein, enoyl-ACP reductase reduces the C2–C3 double bond of enoyl-ACP into a saturated acyl-ACP using one molecule NADPH as the electron donor. The production of butyryl-ACP thus marks the completion of the first cycle of fatty acid elongation, and the reaction sequence thereafter repeats again (condensation → reduction → dehydration → reduction). At the beginning of the second cycle, butyryl-ACP condenses with a molecule of malonyl-ACP, forming the six-carbon β-ketoacyl-ACP molecule and one molecule of CO2. The next three reactions within the second cycle (reduction → dehydration → reduction) convert the six-carbon β-ketoacyl-ACP into a six-carbon ACP molecule, which thus marks the completion of the second cycle of fatty acid elongation, and a third cycle can thereafter begin. These elongation cycles continue (x7) until a (16C) acyl-ACP molecule is formed.
The Sanitary Commission for the Eradication of Hookworm Disease was a Rockefeller-funded campaign from 1909 to 1914 to study and treat hookworm disease in 11 Southern states. Hookworm was known as the "germ of laziness". In 1913, the foundation expanded its work with the Sanitary Commission abroad and set up the International Health Division (also known as International Health Board), which began the foundation's first international public health activities. The International Health Division conducted campaigns in public health and sanitation against malaria, yellow fever, and hookworm in areas throughout Europe, Latin America and the Caribbean including Italy, France, Venezuela, Mexico, and Puerto Rico, totaling fifty-two countries on six continents and twenty-nine islands. The first director was Wickliffe Rose, followed by F.F. Russell in 1923, Wilbur Sawyer in 1935, and George Strode in 1944. A number of notable physicians and field scientists worked on the international campaigns, including Lewis Hackett, Hideyo Noguchi, Juan Guiteras, George C. Payne, Livingston Farrand, Cornelius P. Rhoads, and William Bosworth Castle. In 1936, The Rockefeller Foundation received one of the first awarded Walter Reed Medals from The American Society of Tropical Medicine & Hygiene to recognize its study and control of Yellow Fever. The World Health Organization, seen as a successor to the IHD, was formed in 1948, and the IHD was subsumed by the larger Rockefeller Foundation in 1951, discontinuing its overseas work.
=== Interactions === When two or more vaccines are mixed in the same formulation, the two vaccines can interfere. This most frequently occurs with live attenuated vaccines, where one of the vaccine components is more robust than the others and suppresses the growth and immune response to the other components. This phenomenon was noted in the trivalent Sabin polio vaccine, where the relative amount of serotype 2 virus in the vaccine had to be reduced to stop it from interfering with the "take" of the serotype 1 and 3 viruses in the vaccine. To accomplish this, the doses of serotypes 1 and 3 were increased in the vaccine in the early 1960s. It was also noted in a 2001 study to be a problem with dengue vaccines, where the DEN-3 serotype was found to predominate and suppress the response to DEN-1, -2 and -4 serotypes.
==== Effect on the company and bankruptcy ==== The value of the company plunged as a result of the scandal. On 24 September, Fonterra announced it had written down the carrying value of its investment by NZ$139 million (two-thirds), reflecting the costs of product recall and the impairment of the 'Sanlu' brand because of the "criminal contamination of milk". By 27 September, China Daily reported Sanlu was close to bankruptcy, and might be taken over by the Beijing Sanyuan Foods Company. The company is also facing lawsuits from parents (see Anger at Sanlu). The Beijing Review said Sanlu expects to have to pay compensation claims totalling ¥700 million, and it became clear the company would be broken up and sold. On 25 December, Shijiazhuang court accepted a creditor's bankruptcy petition against Sanlu. Media commentators expected the Sanlu distribution network to be sold.
== Chemical synthesis == Microbial catabolism of phytosterol side chains yields C-19 steroids, C-22 steroids, and 17-ketosteroids (i.e. precursors to adrenocortical hormones and contraceptives). The addition and modification of functional groups is key when producing the wide variety of medications available within this chemical classification. These modifications are performed using conventional organic synthesis and/or biotransformation techniques.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.